Combating infectious diseases and cancer with precision vaccines

Who We Are

Virometix AG is a clinical stage biotech company pioneering a new class of synthetic vaccines to tackle infectious diseases and cancer.

Our structure-based vaccines are designed to direct a precise, robust and sustained immune response. With a proprietary modular and fully synthetic nanoparticle technology platform, our vaccines are purposefully designed, are safe, and of low cost and scalable production. Our lead indication for Streptococcus pneumoniae infections targets a high unmet need.


A purposefully designed immune protection. A flexible, modular synthetic technology platform that offers competitive advantages.

Our synthetic nanoparticle delivery platform leads to safe and efficacious vaccines. With a structure-guided and algorithm-aided approach we design immunogens that mimic protective epitopes on infectious agents and display them in multivalent form on highly immunogenic, self-adjuvanted particles.


Our technology platform lends itself to a wide range of applications

We are developing a portfolio of products highlighted by a serotype-independent vaccine candidate against Streptococcus pneumoniae, a first-in-class vaccine candidate for Respiratory Syncytial Virus (RSV) and and Coronaviruses prophylactic approaches

Grants & Awards

Our awards include the following